Ortho Preserve

Meniscus Implant for Knee Pain Treatment

Cover Block

Field	Value
Name	OrthoPreserve
Tagline	Meniscus Implant for Knee Pain Treatment
Headquarters	Atlanta, Georgia
Founded	2021
Industry	Medical Devices, Orthopedics
Technology	Implantable meniscus replacement
Geography	North America
Founding Team	Jonathan Schwartz (Georgia Tech alum)
Funding Label	NIH SBIR grant

Summary and Signal

OrthoPreserve is an Atlanta-based medical device startup developing a synthetic meniscus implant intended to treat knee pain in patients whose native meniscus tissue cannot be repaired. The company was spun out of Georgia Tech in 2021 by founder Jonathan Schwartz, whose graduate research formed the technical basis of the device [Georgia Tech, July 2024]; [Hypepotamus]. In early 2025, OrthoPreserve announced that the U.S. Food and Drug Administration granted the implant Breakthrough Device Designation and accepted it into the agency's Total Product Life Cycle Advisory Program (TAP) [PR Newswire]. Disclosed financing to date includes a National Institutes of Health SBIR grant, with Activation Capital named as an investor and the Advanced Technology Development Center (ATDC) at Georgia Tech named as the supporting accelerator [CB Insights]; [Southeast Venture Showcase]. Identified competitors in the meniscus segment include Active Implants and Orteq Ltd, alongside larger orthopedic incumbents such as Stryker [CB Insights]. The company remains pre-clinical; the next 12 to 18 months will be defined by the structure of the FDA-aligned clinical study, the size and lead of any priced equity round, and whether early surgeon advisors translate into named clinical investigators.

Data Accuracy: GREEN -- Confirmed by PR Newswire, Georgia Tech News Center, CB Insights, and Hypepotamus.

Taxonomy Snapshot

Axis	Value
Industry / Vertical	Medical Devices, Orthopedics (meniscus replacement)
Technology Type	Implantable synthetic meniscus
Geography	North America (Atlanta, GA)
Founding Team	Solo technical founder, university spinout
Funding	NIH SBIR grant; Activation Capital named investor

Company Overview

OrthoPreserve traces its origin to a graduate thesis at the Georgia Institute of Technology, where founder Jonathan Schwartz worked on an implantable meniscus replacement intended to preserve native knee biomechanics [Georgia Tech, July 2024]; [Hypepotamus]. The company was incorporated in 2021 and is headquartered in Atlanta, where it has continued to develop the device through Georgia Tech's commercialization pathway and the Advanced Technology Development Center (ATDC) [Georgia Tech, July 2024]; [CB Insights].

In early 2025, the FDA granted the meniscus implant Breakthrough Device Designation and admitted the program into the Total Product Life Cycle Advisory Program (TAP) [PR Newswire]. Breakthrough Designation is reserved for devices that target serious or irreversibly debilitating conditions and offer advantages over existing approved alternatives, and TAP enrollment provides structured access to FDA staff and strategic stakeholders.

Financing disclosures are limited. Public databases and the company's showcase profile reference an NIH SBIR grant and name Activation Capital as an investor [CB Insights]; [Southeast Venture Showcase].

Data Accuracy: GREEN -- Confirmed by Georgia Tech News Center, PR Newswire, and CB Insights.

The Product and the Stack

The core product is a synthetic meniscus implant intended to replace damaged meniscal tissue in the knee, positioned as an alternative to partial meniscectomy and as a delay or substitute for total knee arthroplasty [PR Newswire]; [Hypepotamus]. The device is designed to restore the meniscus's load-distribution function in the knee joint [OrthoPreserve].

From a regulatory standpoint, the program is at the pre-clinical stage and is being shepherded under the FDA's Breakthrough Devices and TAP frameworks [PR Newswire]. TAP enrollment adds structured engagement with payers, providers, and investors during product development [PR Newswire].

Data Accuracy: YELLOW -- Product positioning confirmed by PR Newswire and Hypepotamus; technical specifics not publicly disclosed.

Market Research and Opportunity

Meniscus injury is a frequent indication for arthroscopic knee surgery in the United States. Partial meniscectomy is associated with elevated risk of post-traumatic osteoarthritis and eventual total knee replacement. The addressable opportunity for a durable meniscus replacement is the avoided downstream cost of arthroplasty in younger patients.

The broader knee reconstruction and orthopedic reconstructive device market is dominated by large public players including Stryker, Zimmer Biomet, and Smith & Nephew [CB Insights].

Market signal	Detail
FDA Breakthrough Device Designation	Granted for OrthoPreserve meniscus implant
FDA TAP enrollment	Accepted into Total Product Life Cycle Advisory Program
Named competitors in segment	Active Implants, Orteq Ltd, Stryker (adjacent)

Data Accuracy: YELLOW -- Regulatory milestones confirmed by PR Newswire; market sizing inferred from public company disclosures.

The Competitive Field

OrthoPreserve is positioned in a category of meniscus replacement and meniscus-preserving implants.

Company	Positioning	Stage / Funding
OrthoPreserve	Synthetic meniscus implant for knee pain	Pre-clinical; NIH SBIR + Activation Capital
Active Implants	NUsurface meniscus implant	Commercial outside U.S.; clinical in U.S.
Orteq Ltd	Actifit meniscal scaffold	Commercial in select markets
Stryker	Knee reconstruction and cartilage repair franchises	Public (NYSE: SYK)

Focused meniscus replacement programs compete on whether a synthetic or scaffold device can deliver durable, load-bearing function. Adjacent biologic and cartilage-repair products compete for the same surgeon decision at the point of arthroscopy. Large reconstruction incumbents like Stryker own the downstream arthroplasty market that any successful meniscus preservation device would partially cannibalize.

Data Accuracy: YELLOW -- OrthoPreserve milestones confirmed by PR Newswire; competitor positioning drawn from CB Insights category data.

Opportunity

If OrthoPreserve reaches the U.S. market with a meniscus implant supported by durable clinical data, the size of the prize is the share of the multi-billion dollar knee reconstruction economy that shifts upstream into preservation.

Scenario	What happens
Strategic acquisition	A large orthopedic player buys OrthoPreserve to add a preservation device to its knee franchise
Independent U.S. launch	OrthoPreserve raises a clinical-stage round, runs its pivotal trial, and launches with a focused U.S. team
Category standard	The OrthoPreserve device becomes the reference implant for synthetic meniscus replacement

Data Accuracy: YELLOW -- Regulatory and competitor anchors confirmed by PR Newswire and CB Insights; financial outcomes presented as scenarios.

Sources

[PR Newswire] OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant | https://www.prnewswire.com/news-releases/orthopreserve-receives-both-fda-breakthrough-device-designation-and-prestigious-tap-enrollment-for-meniscus-implant-to-rework-knee-pain-treatment-302363541.html
[Georgia Tech, July 2024] Tech Alum Launches Meniscus Implant Startup | https://news.gatech.edu/news/2024/07/11/tech-alum-launches-meniscus-implant-startup
[Georgia Tech Research] Tech Alum Launches Meniscus Implant Startup | https://research.gatech.edu/tech-alum-launches-meniscus-implant-startup
[CB Insights] OrthoPreserve - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/orthopreserve
[Hypepotamus] CEO Q&A: How A Graduate Thesis Turned Into MedTech Startup OrthoPreserve | https://hypepotamus.com/news/ceo-qa-how-a-graduate-thesis-turned-into-medtech-startup-orthopreserve/
[Southeast Venture Showcase] OrthoPreserve, Inc. | https://southeastventureshowcase.com/teams/orthopreserve-inc
[OrthoPreserve] Mission - OrthoPreserve: Meniscus Implant for Knee Pain Treatment | https://www.orthopreserve.com/mission

Articles about Ortho Preserve

OrthoPreserve Is Building a Replacement Meniscus for the Knee Surgeon's Tray — The Atlanta startup, spun out of Georgia Tech, has FDA Breakthrough status for an implant aimed at patients who today get a partial meniscectomy and a countdown to arthritis.

View on Startuply.vc